What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2025-12-15 compared with 2024-12-26 · 63 added, 62 removed, 4 unchanged (97% of the section changed)

Legal Proceedings.

We are not currently a party

to any material litigation or other legal proceedings brought against us.

We are also not aware of any legal proceeding, investigation

or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial

condition or results of operations.

are not currently a party to any material litigation or other legal proceedings brought against us.

We are also not aware of any legal

proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect

on our business, financial condition or results of operations.

Mine Safety Disclosures.

Not applicable.

Market Information.

Our Public Units, Class

A Ordinary Shares and Rights are each traded on The Nasdaq Capital Market under the symbols “EURKU,” “EURK” and

“EURKR,” respectively.

Public Units, Class A Ordinary Shares and Rights are each traded on The Nasdaq Capital Market under the symbols “EURKU,”

“EURK” and “EURKR,” respectively.

of the date hereof, we had 2 holders of record of our units, 2 holders of record of our separately traded Class A Ordinary Shares, 4

holders of record of our Class B Ordinary Shares and 1 holder of record of our separately traded Rights.

The number of record holders

was determined from the records of our transfer agent.

have not paid any cash dividends on our Ordinary Shares to date and do not intend to pay cash dividends prior to the completion of our

initial business combination.

The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital

requirements and general financial condition subsequent to completion of our initial business combination.

The payment of any cash dividends

subsequent to our initial business combination will be within the discretion of our board of directors at such time.

In addition, our

board of directors is not currently contemplating and does not anticipate declaring any share dividends in the foreseeable future.

if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends may be limited by

restrictive covenants we may agree to in connection therewith.

Authorized for Issuance Under Equity Compensation Plans

Sales of Unregistered Securities;

Use of Proceeds from Registered Offerings

July 4, 2023 and September 29, 2023, the Sponsor acquired 100 and 1,437,400 Class B ordinary shares, par value $0.0001 per share (the

“Founder Shares”), respectively, for an aggregate purchase price of $25,000, or approximately $0.02 per share.

2024, the Sponsor entered into a securities transfer agreement, pursuant to which the Sponsor transferred 10,000 Founder Shares to each

of our independent directors, Dr.

Anthony Wong (former director), Ms.

Lauren Simmons and Kevin McKenzie, at the original purchase

price, immediately prior to the closing of the IPO.

The issuance of such Class B Ordinary Shares to the Sponsor was made pursuant to

the exemption from registration under Section 4(a)(2) of the Securities Act.

July 3, 2024, we consummated the IPO of 5,000,000 Units, generating gross proceeds of $50,000,000.

Maxim Group LLC acted as representative

of the underwriters.

The securities sold in the IPO were sold pursuant to a registration statement on Form S-1 (File No.:

The registration statement became effective on July 1, 2024.

July 3, 2024, substantially concurrently with the closing of the IPO, we completed the Private Placement of 216,750 Initial Private Units

to the Sponsor at a purchase price of $10.00 per Initial Private Unit, generating gross proceeds to us of $2,167,500.

The issuance of

the Initial Private Units was made pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act.

We also issued

to the Representative, 230,000 Class A Ordinary Shares as part of the underwriting compensation (the “Representative Shares”)

on the closing of the IPO.

proceeds of $50,000,000 ($10.00 per Public Unit) in the aggregate from the IPO and the Private Placement, were placed in the Trust Account.

July 8, 2024, 750,000 Option Units were sold to the Representative upon its exercise of the Over-Allotment Option, at an offering price

of $10.00 per Option Unit, generating gross proceeds of $7,500,000.

Simultaneously with the issuance and sale of the Option Units, the

Company completed a private placement sale of an additional 11,250 Additional Private Unit to the Sponsor at a purchase price of $10.00

per Additional Private Unit, generating gross proceeds of $112,500.

In connection with the issuance and sales of the Option Units, the

Company issued an additional 30,000 Representative Shares to the Representative.

proceeds of $57.5 million ($10.00 per Public Unit) in the aggregate from the IPO and the Private Placement were placed in the Trust Account.

As of the date hereof, we

had 2 holders of record of our units, 2 holders of record of our separately traded Class A Ordinary Shares, 7 holders of record of our

Class B Ordinary Shares and 1 holder of record of our separately traded Rights.

The number of record holders was determined from the records

of our transfer agent.

We have not paid any cash

dividends on our Ordinary Shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination.

The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general

financial condition subsequent to completion of our initial business combination.

The payment of any cash dividends subsequent to our

initial business combination will be within the discretion of our board of directors at such time.

In addition, our board of directors

is not currently contemplating and does not anticipate declaring any share dividends in the foreseeable future.

Further, if we incur any

indebtedness in connection with our initial business combination, our ability to declare dividends may be limited by restrictive covenants

we may agree to in connection therewith.

Securities Authorized for Issuance Under Equity

Compensation Plans

Recent Sales of Unregistered Securities;

of Proceeds from Registered Offerings

On July 4, 2023 and September 29, 2023, the Sponsor acquired 100 and

1,437,400 Class B ordinary shares, par value $0.0001 per share (the “Founder Shares”), respectively, for an aggregate purchase

price of $25,000, or approximately $0.02 per share.

On June 27, 2024, the Sponsor entered into a securities transfer agreement, pursuant

to which the Sponsor transferred 10,000 Founder Shares to each of our independent directors, Dr.

Anthony Wong, Ms.

Lauren Simmons and

Kevin McKenzie, at the original purchase price, immediately prior to the closing of the IPO.

The issuance of such Class B Ordinary Shares

to the Sponsor was made pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act.

On July 3, 2024, we consummated

the IPO of 5,000,000 Units, generating gross proceeds of $50,000,000.

Maxim Group LLC acted as representative of the underwriters.

securities sold in the IPO were sold pursuant to a registration statement on Form S-1 (File No.:

The registration statement

became effective on July 1, 2024.

On July 3, 2024, substantially concurrently with the closing of the

IPO, we completed the Private Placement of 216,750 Initial Private Units to the Sponsor at a purchase price of $10.00 per Initial Private

Unit, generating gross proceeds to us of $2,167,500.

The issuance of the Initial Private Units was made pursuant to the exemption from

registration under Section 4(a)(2) of the Securities Act.

We also issued to the Representative, 230,000 Class A Ordinary Shares as part

of the underwriting compensation (the “Representative Shares”) on the closing of the IPO.

The proceeds of $50,000,000

($10.00 per Public Unit) in the aggregate from the IPO and the Private Placement, were placed in the Trust Account.

On July 8, 2024, 750,000 Option Units were sold to the Representative

upon its exercise of the Over-Allotment Option, at an offering price of $10.00 per Option Unit, generating gross proceeds of $7,500,000.

Simultaneously with the issuance and sale of the Option Units, the Company completed a private placement sale of an additional 11,250

Additional Private Unit to the Sponsor at a purchase price of $10.00 per Additional Private Unit, generating gross proceeds of $112,500.

In connection with the issuance and sales of the Option Units, the Company issued an additional 30,000 Representative Shares to the Representative.

The proceeds of $57.5 million

($10.00 per Public Unit) in the aggregate from the IPO and the Private Placement were placed in the Trust Account.

Purchases of Equity Securities by the Issuer

and Affiliated Purchasers

issued five Extension Notes in the aggregate principal amount of $750,000 to the Sponsor.

As of the date hereof, we issued one Working

Capital Note in the principal amount of up to $300,000 to the Sponsor.

The proceeds of the Working Capital Note, which may be drawn down

from time to time until the Company consummates its initial business combination, will be used as general working capital purposes.

Notes bear no interest and are payable in full upon the earlier to occur of (i) the consummation of the Company’s business combination

or (ii) the date of expiry of the term of the Company.

The Sponsor, has the right, but not the obligation, to convert the Notes, in whole

or in part, respectively, into the Conversion Units.

of Equity Securities by the Issuer and Affiliated Purchasers

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings